Epigenetics describes biological processes that cells use to control whether genes are turned on or off without altering the DNA itself. Disrupting epigenetic mechanisms can drive the development of cancer.

Unlike genetic changes, epigenetic modifications are frequently reversible, thus providing opportunities for a new kind of therapy called epigenetic therapy. Using this tactic, targeted therapies cause specific epigenetic changes that return the expression of DNA to its precancerous condition.

Building on the successes of the original SU2C Epigenetics Dream Team, the VAI–SU2C Epigenetics Dream Team II continues to apply epigenetic therapies in combination with other treatments to multiple types of cancer, with clinical trials in three categories: immune sensitization, chemo sensitization and novel target strategies.

In its immune sensitization work, the team has combined epigenetic agents with immune checkpoint therapy in lung, blood and multiple solid cancer patients.

The team’s chemo sensitization strategy involves testing a new epigenetic agent on chemotherapy-resistant colorectal cancer.

The novel targeting strategies category comprises multiple projects including a trial using an epigenetic agent with a PARP inhibitor in acute myeloid leukemia patients and a study of combining a vitamin C supplement with epigenetic agents in blood cancer patients.